Hubei Goto Biopharm Co.,Ltd. (SHE:300966)

Hubei Goto Biopharm Revenue

Hubei Goto Biopharm had revenue of 161.94M CNY in the quarter ending March 31, 2026, with 16.32% growth. This brings the company's revenue in the last twelve months to 628.90M, up 13.61% year-over-year. In the year 2025, Hubei Goto Biopharm had annual revenue of 606.18M with 12.97% growth.

• Revenue (ttm): 628.90M
• Revenue Growth: +13.61%
• P/S Ratio: 5.02
• Revenue / Employee: 769.77K
• Employees: 817
• Market Cap: 3.16B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	606.18M	69.58M	12.97%
Dec 31, 2024	536.60M	-29.80M	-5.26%
Dec 31, 2023	566.40M	-38.17M	-6.31%
Jan 1, 2023	604.57M	13.69M	2.32%
Jan 1, 2022	590.89M	122.77M	26.23%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 10, 2026

Data Sources Report a data error